Literature DB >> 12547608

Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes.

Carmen Arigita1, Gideon F A Kersten, Ton Hazendonk, Wim E Hennink, Daan J A Crommelin, Wim Jiskoot.   

Abstract

The impact of the conformation, lipooligosaccharide (LOS)-depletion and the presentation form of outer membrane protein PorA from Neisseria meningitidis (PorA) subtype P1.7-2,4 on the immune response in mice was studied. Native PorA was purified from outer membrane vesicles (OMVs) derived from meningococci and reconstituted into liposomes. The conformation of PorA after purification from OMVs and reconstitution in liposomes was monitored by use of electrophoretic and spectroscopic techniques and compared with the conformation of PorA in outer membrane complexes (OMCs) and heat-denatured PorA. The antigenicity of the PorA formulations was measured by ELISA by using a bactericidal anti-P1.4 monoclonal antibody. Immunogenicity was determined in Balb/c mice. PorA-specific IgG, isotype distribution and bactericidal activity were measured after subcutaneous immunization. In all formulations except in heat-denatured OMVs, PorA was present as trimers. The lipooligosaccharide (LOS) content was reduced by 96% in the purified protein with respect to the original OMVs. The antigenicity of purified PorA (i.e. ELISA response) was substantially higher as compared to PorA in liposomes, OMVs or OMCs. The results of the immunogenicity studies showed that all formulations were able to induce comparable IgG titers. However, whereas the antibodies raised by OMVs were bactericidal, the antibodies elicited by immunization with purified PorA were unable to kill meningococci. Remarkably, the ability to induce bactericidal antibodies was fully recovered by incorporation of the purified PorA into liposomes, in the absence of other adjuvants, as compared to LOS-containing OMVs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547608     DOI: 10.1016/s0264-410x(02)00546-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.

Authors:  Thomas A Luijkx; Jacqueline A M van Gaans-van den Brink; Harry H van Dijken; Germie P J M van den Dobbelsteen; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2008-09-03

3.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

4.  Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.

Authors:  Gregory A Price; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.

Authors:  Rachel M Stenger; Mieke Smits; Betsy Kuipers; Sabine F M Kessen; Claire J P Boog; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

6.  Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response.

Authors:  Carmen Arigita; Lisette Bevaart; Linda A Everse; Gerben A Koning; Wim E Hennink; Daan J A Crommelin; Jan G J van de Winkel; Martine J van Vugt; Gideon F A Kersten; Wim Jiskoot
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

7.  An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity.

Authors:  Gunnstein Norheim; Holly Sanders; Jardar W Mellesdal; Idunn Sundfør; Hannah Chan; Carina Brehony; Caroline Vipond; Chris Dold; Rory Care; Muhammad Saleem; Martin C J Maiden; Jeremy P Derrick; Ian Feavers; Andrew J Pollard
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

8.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.

Authors:  Ojas H Mehta; Gunnstein Norheim; J Claire Hoe; Christine S Rollier; Jerry C Nagaputra; Katherine Makepeace; Muhammad Saleem; Hannah Chan; David J P Ferguson; Claire Jones; Manish Sadarangani; Derek W Hood; Ian Feavers; Jeremy P Derrick; Andrew J Pollard; E Richard Moxon
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

10.  Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells.

Authors:  Claire Jones; Manish Sadarangani; Susan Lewis; Isabelle Payne; Muhammad Saleem; Jeremy P Derrick; Andrew J Pollard
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.